Capricor Therapeutics Stock Price Surges 6.6%

Analysts Weigh In on Biotech Firm's Promising Outlook

Apr. 4, 2026 at 9:52am

Got story updates? Submit your updates here. ›

Capricor Therapeutics, Inc. (NASDAQ:CAPR) saw its stock price jump 6.6% on Thursday, trading as high as $31.02 per share. The biotech firm, headquartered in Beverly Hills, California, has advanced its lead candidate CAP-1002 through multiple clinical trials and built a pipeline spanning cell therapy and exosome platforms.

Why it matters

Capricor Therapeutics is a clinical-stage biotech company focused on developing innovative cell and exosome-based treatments for cardiovascular and rare diseases. The surge in its stock price reflects growing investor confidence in the company's pipeline and technology, which could lead to breakthroughs in areas like Duchenne muscular dystrophy and COVID-19-related heart injury.

The details

Capricor Therapeutics' stock price closed at $32.12 on Thursday, up from $30.12 the previous day. Trading volume was 184,252 shares, down 87% from the average session volume of 1,370,198 shares. Several equity research analysts have recently weighed in on the stock, with UBS Group setting a $50 price target and Cantor Fitzgerald issuing an 'overweight' rating with a $62 price target.

  • Capricor Therapeutics' stock price shot up 6.6% on Thursday, April 4, 2026.
  • The company's stock previously closed at $30.12 on the prior trading day.

The players

Capricor Therapeutics, Inc.

A clinical-stage biotechnology company focused on developing cell and exosome-based therapies for cardiovascular and rare diseases. The company is headquartered in Beverly Hills, California.

UBS Group

A global investment bank and financial services firm that has set a $50 price target on Capricor Therapeutics' stock.

Cantor Fitzgerald

A global financial services firm that has issued an 'overweight' rating on Capricor Therapeutics' stock with a $62 price target.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.